Pharmacosmos - CDMO/CMO

Drug substance manufacturing is the development and production of the active ingredient (API) used in a medicine. It often includes process development, scale-up, GMP manufacturing, analytical methods, and documentation for target markets.

A pharmaceutical CDMO is a contract partner that provides development and manufacturing services, often end-to-end: process development, scale-up, tech transfer, validation, and GMP production (CDMO manufacturing).

Many drug substance partners offer both CDMO execution and CRO-style support, such as specialized analytical development, feasibility work, and early-stage research services. The right choice depends on scope, not the label.

Involve CRO support when you need specialized analytical development, rapid feasibility work, or research-heavy services that complement the CDMO scope. Many buyers use CDMO services for development + manufacturing and add CRO services for specific tasks.

Start with scope (development vs manufacturing), then match capability (chemistry/biology, potency, scale), validate GMP credentials and supported markets (FDA/EMA/PMDA), and finally check capacity and lead times.

Include API type, stage, batch sizes and annual demand estimate, target markets, known impurities/critical quality attributes, required containment/OEB, timeline, and which services you expect (process development, tech transfer, GMP manufacturing, QC).

If potency or OEB limits require closed handling and validated containment, shortlist partners with dedicated suites, documented exposure controls, and experience with similar compounds at comparable scales.

Very. In-house analytical development and QC often reduce transfer friction and shorten timelines. Ask what is truly in-house (methods, stability, impurity profiling) versus outsourced.

Look for relevant inspections/certifications aligned to your target markets (FDA, EMA, etc.), and confirm that the specific facility and suites are in-scope. Mature quality systems (deviations/CAPA, change control) matter as much as certificates.

Process complexity, containment requirements, analytical method readiness, documentation needs for target markets, and capacity constraints. Clear scope and good transfer documentation reduce delays.

Sometimes, but often facilities and expertise differ. Validate modality fit (biologics vs chemical-synthetic), equipment and containment, and comparable project references.

Compare on scope (what’s included), proven experience at similar scales, GMP maturity, analytical capabilities, supported markets, lead times, and how change control and deviations are handled. Use filters above to remove obvious mismatches first.